We are live on ! Find out more
BBLG

Bone Biologics
BBLG

4 hedge funds and large institutions have $89.1K invested in Bone Biologics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,505% more capital invested

Capital invested by funds: $5.56K → $89.1K (+$83.6K)

100% more funds holding

Funds holding: 2 → 4 (+2)

4.44% more ownership

Funds ownership: 0.31% → 4.76% (+4.4%)

Holders
4
Holders Change
+2
Holders Change %
+100%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$120K
2
TRCT
Tower Research Capital (TRC)
New York
+$9.84K
3
UBS Group
UBS Group
Switzerland
+$1.95K

Top Sellers

No sellers this quarter

BBLG Hedge Fund Activity: Q1 2024 in Review

4 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q1 2024, worth a combined $89.1K — up 1,505% from $5.56K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new BBLG positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $120K.

  • 4 institutional investors held Bone Biologics (BBLG) as of Q1 2024, up from 2 in Q4 2023.
  • Funds reported $89.1K of Bone Biologics stock for Q1 2024, up 1,505% quarter-over-quarter.
  • 2 funds opened new Bone Biologics positions in Q1 2024 and 0 closed out, a net change of +2 holders.
  • The largest Bone Biologics buyer in Q1 2024 was Armistice Capital, an estimated $120K added.

Based on aggregated 13F filings for Q1 2024.